Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer
暂无分享,去创建一个
S. Larson | Jason S. Lewis | H. Lilja | M. McDevitt | N. Mitsiades | S. Strand | D. Veach | Philip A. Watson | D. Abou | D. Thorek | S. Sharma | Sai Kiran Sharma | D. Ulmert | Anson T. Ku | Dipti Metha | Jason S. Lewis
[1] D. Katsaros,et al. Prostate-specific antigen in serum of women with breast cancer. , 1995, British Journal of Cancer.
[2] G. Colditz,et al. Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women , 2011, Clinical Cancer Research.
[3] V. Kosma,et al. Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women , 1999, British Journal of Cancer.
[4] B. V. VON Schoultz,et al. Binding of levonorgestrel, norethisterone and desogestrel to human sex hormone binding globulin and influence on free testosterone levels. , 1989, Gynecologic and Obstetric Investigation.
[5] R. Sitruk-Ware. New progestagens for contraceptive use. , 2006, Human reproduction update.
[6] H. Lilja,et al. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection , 2013, Thrombosis and Haemostasis.
[7] N. Socci,et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.
[8] R. Bryan,et al. Androgen receptors in breast cancer , 1984, Cancer.
[9] D. Tindall,et al. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions , 2000, British Journal of Cancer.
[10] S. Larson,et al. Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution. , 2015, Nuclear medicine and biology.
[11] C. Boni,et al. Therapeutic activity of testosterone in metastatic breast cancer. , 2014, Anticancer research.
[12] H. Lilja,et al. Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a 111In-radiolabelled monoclonal antibody, 11B6 , 2014, EJNMMI Research.
[13] E. Diamandis,et al. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines , 2004, Breast Cancer Research and Treatment.
[14] Kim Pettersson,et al. Development of sensitive immunoassays for free and total human glandular kallikrein 2. , 2004, Clinical chemistry.
[15] H. Scher,et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.
[16] L. Al-Naama,et al. Serum level of prostate-specific antigen (PSA) in women with breast cancer. , 2013, Cancer epidemiology.
[17] A. Phillips. The Selectivity of a New Progestin , 1990, Acta obstetricia et gynecologica Scandinavica. Supplement.
[18] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[19] D. Scheinberg,et al. Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.
[20] S. Hilsenbeck,et al. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells , 2010, Breast Cancer Research and Treatment.
[21] P. Sismondi,et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue , 2005, Breast Cancer Research and Treatment.
[22] T. Traina,et al. Triple-Negative Breast Cancer: Role of the Androgen Receptor , 2010, Cancer journal.
[23] A. E. Lemus,et al. Molecular interactions of Levonorgestrel and its 5α-reduced derivative with androgen receptors in hamster flanking organs , 1995, Steroids.
[24] S. Larson,et al. Internalization of secreted antigen–targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis , 2016, Science Translational Medicine.
[25] P. Sismondi,et al. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. , 1995, Cancer research.
[26] I. Tannock,et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.
[27] Myles A Brown,et al. Targeting the Androgen Receptor in Breast Cancer , 2015, Current Oncology Reports.
[28] R Krattenmacher,et al. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. , 2000, Contraception.
[29] P Sismondi,et al. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] T. Tran,et al. Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2 , 2016, EJNMMI Research.
[31] K. Pienta,et al. VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.
[32] P. Darney. The androgenicity of progestins. , 1995, The American journal of medicine.
[33] S. X. Liu,et al. Mutagenic effects of a single and an exact number of alpha particles in mammalian cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[34] S. Koide,et al. Nestorone®: a progestin with a unique pharmacological profile , 2000, Steroids.
[35] J. Weidhaas,et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] S. Larson,et al. Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer , 2018, Nature Communications.
[37] Q. Sun,et al. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis , 2016, Oncotarget.
[38] Jinbao Liu,et al. Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide , 2019, Journal of Experimental & Clinical Cancer Research.
[39] E. Diamandis,et al. The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast , 2004, Breast Cancer Research and Treatment.
[40] E. Scarpi,et al. Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? , 2018, Front. Endocrinol..
[41] K. Lee,et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] Paul E Swanson,et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. , 2003, American journal of clinical pathology.
[43] M. Shehata,et al. Androgen receptor expression in estrogen receptor-negative breast cancer , 2018 .